US 9,809,617 B2
Crystal form of regadenoson and preparation method thereof
Wei Liu, Shanghai (CN); Zhigang Zhang, Shanghai (CN); and Qin Bao, Shanghai (CN)
Assigned to Shanghai Ziyuan Pharmaceutical Co., Ltd., Shanghai (CN)
Filed by Shanghai Ziyuan Pharmaceutical Co., Ltd., Minhang, Shanghai (CN)
Filed on Jul. 3, 2015, as Appl. No. 14/791,290.
Prior Publication US 2017/0002036 A1, Jan. 5, 2017
Int. Cl. C07H 19/16 (2006.01); C07H 19/167 (2006.01)
CPC C07H 19/16 (2013.01) [C07H 19/167 (2013.01)] 6 Claims
 
1. A crystal form E of regadenoson, which is characterized in that, it has an X-ray powder diffraction pattern substantively as shown in FIG. 5; and
an absorption peak at about 221.02° C. in differential scanning calorimetric analysis curve thereof.